Literature DB >> 11546794

Heregulin-dependent activation of phosphoinositide 3-kinase and Akt via the ErbB2/ErbB3 co-receptor.

N J Hellyer1, M S Kim, J G Koland.   

Abstract

The ErbB2/ErbB3 heregulin co-receptor has been shown to couple to phosphoinositide (PI) 3-kinase in a heregulin-dependent manner. The recruitment and activation of PI 3-kinase by this co-receptor is presumed to occur via its interaction with phosphorylated Tyr-Xaa-Xaa-Met (YXXM) motifs occurring in the ErbB3 C terminus. In this study, mutant ErbB3 receptor proteins expressed in COS7 cells were used to investigate PI 3-kinase-dependent signaling pathways activated by the ErbB2/ErbB3 co-receptor. We observed that a mutant ErbB3 protein with each of its six YXXM motifs containing a Tyr --> Phe substitution was unable to bind either the p85 regulatory or p110 catalytic subunit of PI 3-kinase. However, restoration of a single YXXM motif was sufficient to mediate association with the PI 3-kinase holoenzyme, although at a lower level than wild-type ErbB3. When ErbB3 YXXM motifs were restored in pairs, evidence for cooperativity between two, those incorporating Tyr-1273 and Tyr-1286, was observed. Interestingly, we have shown that an apparent association of PI 3-kinase activity with ErbB2/Neu was due to the residual presence of ErbB3 in ErbB2 immunoprecipitates. The necessity of ErbB3 association with PI 3-kinase for downstream signaling to the effector kinase Akt was also investigated. Here, the heregulin-dependent translocation of Akt to the plasma membrane and its subsequent activation was observed in intact NIH-3T3 fibroblasts. Recruitment of PI 3-kinase to ErbB3 was required for both activities, and it appeared that ErbB2 activation alone was not sufficient to activate PI 3-kinase signaling in these cells.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11546794     DOI: 10.1074/jbc.M102079200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  51 in total

1.  TLR4/MyD88/PI3K interactions regulate TLR4 signaling.

Authors:  Michelle H W Laird; Sang Hoon Rhee; Darren J Perkins; Andrei E Medvedev; Wenji Piao; Matthew J Fenton; Stefanie N Vogel
Journal:  J Leukoc Biol       Date:  2009-03-16       Impact factor: 4.962

2.  Randomized Phase II Trial of Seribantumab in Combination with Erlotinib in Patients with EGFR Wild-Type Non-Small Cell Lung Cancer.

Authors:  Lecia V Sequist; Jhanelle Elaine Gray; Wael A Harb; Ariel Lopez-Chavez; Robert C Doebele; Manuel R Modiano; David Michael Jackman; Maria Quintos Baggstrom; Akin Atmaca; Enriqueta Felip; Mariano Provencio; Manuel Cobo; Bambang Adiwijaya; Geoffrey Kuesters; Walid S Kamoun; Karen Andreas; J Marc Pipas; Sergio Santillana; Byoung Chul Cho; Keunchil Park; Frances A Shepherd
Journal:  Oncologist       Date:  2019-04-11

Review 3.  Functional impact of sarcopenia in respiratory muscles.

Authors:  Jonathan E Elliott; Sarah M Greising; Carlos B Mantilla; Gary C Sieck
Journal:  Respir Physiol Neurobiol       Date:  2015-10-20       Impact factor: 1.931

4.  Combined Blockade of Activating ERBB2 Mutations and ER Results in Synthetic Lethality of ER+/HER2 Mutant Breast Cancer.

Authors:  Sarah Croessmann; Luigi Formisano; Lisa N Kinch; Paula I Gonzalez-Ericsson; Dhivya R Sudhan; Rebecca J Nagy; Aju Mathew; Eric H Bernicker; Massimo Cristofanilli; Jie He; Richard E Cutler; Alshad S Lalani; Vincent A Miller; Richard B Lanman; Nick V Grishin; Carlos L Arteaga
Journal:  Clin Cancer Res       Date:  2018-10-12       Impact factor: 12.531

5.  Overexpression and gene amplification of EGFR, HER2, and HER3 in biliary tract carcinomas, and the possibility for therapy with the HER2-targeting antibody pertuzumab.

Authors:  Toru Kawamoto; Kazunori Ishige; Melanie Thomas; Yoriko Yamashita-Kashima; Sei Shu; Nobuyuki Ishikura; Shunichi Ariizumi; Masakazu Yamamoto; Kunihiko Kurosaki; Junichi Shoda
Journal:  J Gastroenterol       Date:  2014-08-12       Impact factor: 7.527

6.  Feedback upregulation of HER3 (ErbB3) expression and activity attenuates antitumor effect of PI3K inhibitors.

Authors:  Anindita Chakrabarty; Violeta Sánchez; María G Kuba; Cammie Rinehart; Carlos L Arteaga
Journal:  Proc Natl Acad Sci U S A       Date:  2011-02-28       Impact factor: 11.205

7.  Listeria monocytogenes produces a pro-invasive factor that signals via ErbB2/ErbB3 heterodimers.

Authors:  Maria José Oliveira; Tineke Lauwaet; Georges De Bruyne; Marc Mareel; Ancy Leroy
Journal:  J Cancer Res Clin Oncol       Date:  2004-10-08       Impact factor: 4.553

Review 8.  The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis.

Authors:  M M Moasser
Journal:  Oncogene       Date:  2007-04-30       Impact factor: 9.867

9.  Posttranslational protein knockdown coupled to receptor tyrosine kinase activation with phosphoPROTACs.

Authors:  John Hines; Jonathan D Gough; Timothy W Corson; Craig M Crews
Journal:  Proc Natl Acad Sci U S A       Date:  2013-05-14       Impact factor: 11.205

10.  Heregulin/ErbB3 Signaling Enhances CXCR4-Driven Rac1 Activation and Breast Cancer Cell Motility via Hypoxia-Inducible Factor 1α.

Authors:  Cynthia Lopez-Haber; Laura Barrio-Real; Victoria Casado-Medrano; Marcelo G Kazanietz
Journal:  Mol Cell Biol       Date:  2016-07-14       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.